Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0917801 (insomnia)
 10,606 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The authors analyse the findings of a clinical simple-blind trial of the drug Insidon--Geigy in depressive states. This drug was administered in monotherapy for 28 days in average doses of 150 mg daily in a series of 20 inpatients of both sexes and aged 20-60 years, diagnosed with neurotic depressive state. The efficiency of the treatment and its tolerance were estimated on a special Ciba-Geigy Pharma International investigation card through clinical observation, scoring of clinical items, psychological check-up and Hamilton's scale for depression at 0-7-14-21 and 28 days, paraclinical investigations, computer processing (TIM-S) on the basis of a program (in BETA BASIC language in 3.1 version) necessary for determining the polynomial functions for the significant items of the psychopathological syndrome (anxiety, depression, insomnia). The corroboration of the data of clinical and paraclinical observations with the psychologic examination and the computer-processed data reveals the clinical efficacy of Insidon--Geigy in neurotic depression, its good tolerance and low incidence of side effects.
 ...
PMID:[The treatment of depressive states with opipramol (Insidon--Geigy)]. 281 12

Early adverse effects of a drug may be a manifestation of individual differences in drug metabolism or of different pathologic processes. These differences may influence therapeutic responsiveness. Using data from Ciba-Geigy's multicenter 10-week clinical trial, we studied the relationship between early side effects and subsequent therapeutic response to clomipramine (CMI) in obsessive-compulsive disorder. We used tabular analyses and multiple regression to evaluate associations between early complaints and change in score on the Yale-Brown Obsessive-Compulsive Scale. We also evaluated whether early complaints were drug related (i.e., true side effects). It appeared that dry mouth, constipation, dizziness, insomnia, male impotence, nervousness, palpitation, and tremor reported during the first 4 weeks were predictive of good response to CMI. Myoclonus and tinnitus appeared weakly associated with treatment success. Most of these complaints were reported more by the CMI group than the placebo group, and more during CMI treatment than before. The more common complaints may reflect an individual's ability to metabolize CMI appropriately so that adequate therapeutic blood levels are attained. The less common complaints may reflect a sensitivity to CMI's serotonergic actions.
 ...
PMID:Relationship between early side effects and therapeutic effects of clomipramine therapy in obsessive-compulsive disorder. 883 9